Author:
Irvine E. Jan,Tack Jan,Crowell Michael D.,Gwee Kok Ann,Ke Meiyun,Schmulson Max J.,Whitehead William E.,Spiegel Brennan
Subject
Gastroenterology,Hepatology
Reference87 articles.
1. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?;Corsetti;Neurogastroenterol Motil,2013
2. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Irritable Bowel Syndrome−Clinical Evaluation of Drugs for Treatment. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf. Published May 2012. Accessed January 10, 2015.
3. Guideline on the Evaluation of Medicinal Products for the Treatment of Irritable Bowel Syndrome. Vol 2014,2013
4. Clinical presentation and personality factors are predictors of the response to treatment in patients with functional dyspepsia; a randomized, double-blind placebo-controlled crossover study;Holtmann;Dig Dis Sci,2004
5. Potential biomarkers;Spiller;Gastroenterol Clin N Am,2011
Cited by
96 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献